Study of MLN4924 Plus Azacitidine in Treatment-Naïve Patients With Acute Myelogenous Leukemia (AML) Who Are 60 Years or Older



Status:Completed
Conditions:Blood Cancer, Hematology
Therapuetic Areas:Hematology, Oncology
Healthy:No
Age Range:60 - Any
Updated:8/19/2018
Start Date:April 15, 2013
End Date:April 8, 2018

Use our guide to learn which trials are right for you!

A Phase 1b, Open-Label, Dose-Escalation Study of MLN4924 Plus Azacitidine in Treatment-Naïve Patients With Acute Myelogenous Leukemia Who Are 60 Years or Older

This study is an open-label, multicenter, phase 1b, dose-escalation study of MLN4924 in
combination with azacitidine in adult patients with AML. The patient population will consist
of patients 60 years of age or older, previously diagnosed with World Health
Organization(WHO)-defined AML, who are unlikely to benefit from standard induction therapy
and who have not received definitive treatment for AML or prior treatment with azacitidine or
decitabine.


Inclusion Criteria:

- Patients with WHO-defined AML, 60 years of age or older, who are unlikely to benefit
from standard induction therapy, defined as having at least 1 of the following:

1. Greater than or equal to 75 years of age

2. Antecedent hematologic disease

3. Known adverse cytogenetic risk

4. Eastern Cooperative Oncology Group (ECOG) PS = 2

- Patient must not have received definitive treatment for AML, defined as any prior
chemotherapy with antileukemic activity

- ECOG PS 0 to 2

- Expected survival longer than 3 months from enrollment in the study

- Female patients who are post menopausal, surgically sterile, or agree to practice 2
effective methods of contraception or agree to practice true abstinence

- Male patients who agree to practice effective barrier contraception or agree to
practice true abstinence

- Voluntary written consent must be given before performance of any study-related
procedure

- Suitable venous access for the study-required blood sampling

- Adequate clinical laboratory values during the screening period as specified in the
protocol

- Able to undergo bone marrow aspiration and biopsy at screening

Exclusion Criteria:

- Previous treatment with azacitidine or decitabine

- Known favorable cytogenetic risk

- Any serious medical or psychiatric illness

- Treatment with any investigational products

- Known hypersensitivity to azacitidine or mannitol

- Acute promyelocytic leukemia as diagnosed by morphologic examination of bone marrow,
by fluorescent in situ hybridization or cytogenetics of peripheral blood or bone
marrow, or by other accepted analysis

- Active uncontrolled infection or severe infectious disease

- Major surgery within 14 days before the first dose of study drug

- Life-threatening illness unrelated to cancer

- Clinically uncontrolled central nervous system (CNS) involvement

- Known human immunodeficiency virus (HIV) positive

- Known hepatitis B surface antigen-positive, or known or suspected active hepatitis C
infection

- Known hepatic cirrhosis or severe pre-existing hepatic impairment

- Known cardiac/cardiopulmonary disease

- Left ventricular ejection fraction

- Known moderate to severe chronic obstructive pulmonary disease, interstitial lung
disease, and pulmonary fibrosis

- Body mass index > 40 kg/m²

- Treatment with CYP3A inducers within 14 days before the first dose of MLN4924

- Systemic antineoplastic therapy or radiotherapy within 14 days before the first dose
of study drug, except for hydroxyurea

- Patients who are unwilling or unable to refrain from using hydroxymethylglutaryl
coenzyme A (HMG CoA) reductase inhibitors (statins) starting 5 days before the initial
study drug administration and throughout the study will not be permitted to enroll
We found this trial at
8
sites
?
mi
from
Miami, FL
Click here to add this to my saved trials
1720 2nd Ave S
Birmingham, Alabama 35233
(205) 934-4011 
University of Alabama at Birmingham The University of Alabama at Birmingham (UAB) traces its roots...
?
mi
from
Birmingham, AL
Click here to add this to my saved trials
321 South Columbia Street
Chapel Hill, North Carolina 27599
?
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
?
mi
from
Denver, CO
Click here to add this to my saved trials
4500 San Pablo Road South
Jacksonville, Florida 32224
?
mi
from
Jacksonville, FL
Click here to add this to my saved trials
3322 West End Avenue
Nashville, Tennessee 37203
(615)329-SCRI (7274)
Sarah Cannon Research Institute Sarah Cannon Research Institute (SCRI) is a global strategic research organization...
?
mi
from
Nashville, TN
Click here to add this to my saved trials
San Antonio, Texas 78229
?
mi
from
San Antonio, TX
Click here to add this to my saved trials
450 Serra Mall
Stanford, California 94305
(650) 723-2300
Stanford University Stanford University, located between San Francisco and San Jose in the heart of...
?
mi
from
Stanford, CA
Click here to add this to my saved trials